US VC Spending Dips 3 Percent in Q3 as Bio-Clusters Endure Big Declines | GenomeWeb
NEW YORK (GenomeWeb News) - Private equity destined for biotechnology and pharmaceutical companies nationwide contracted 2.7 percent in the third quarter due in part to a dip in seed and series A venture capital financing, according to Ernst & Young and Dow Jones VentureOne.
The survey, which also showed significant declines in some life science clusters, found that VC spending nationwide fell to 66 deals totaling almost $1.42 billion in 22 sub-regions from 73 deals totaling around $1.46 billion year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.